This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Butterbur (Petasites hybridus) in hay fever

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A study in the British Medical journal has compared the tolerability and effectiveness of butterbur (Petasites hybridus) with cetirizine in 125 patients with seasonal rhinitis.

Butterbur (carbon dioxide extract ZE 339 - standardised for petasin content) did not produce the sedative side-effects associated with antihistamines and was well tolerated. The study said butterbur was similar in effect to cetirizine in the treatment of hay fever.

Though well-designed, there are two criticisms of the study:

  1. the trial showed lack of difference in effectiveness but was too small to show equivalence
  2. the study used a short treatment period of two weeks in context of a condition where symptoms may vary markedly with daily pollen count changes

Petasites hybridus is a shrub that is found in America, Asia and Europe. Petasin, the active constituent of preparations derived Petasites hybridus, is claimed to have anti-inflammatory (anti-leukotriene) and anti-spasmodic activity.

Reference:

  1. BMJ (2002), 334 (7330), 144-6.

 

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.